tirzepatide in nash the SYNERGY-NASH trial, researchers assessed the efficacy and safety of once-weekly in persons with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or severe fibrosis. Full trial results and Plain Language Summary Effects of Tirzepatide on Patients
Description
It has been well established that GLP-1 RA is associated with improved glucose control and weight loss [18]
For example, significant clinical trials such as the LEADER trial for Victoza and the SUSTAIN-6 trial for Ozempic have shown that these medications not only reduce the risk of major cardiovascular events but may also decrease the risk of cardiovascular-related death in this population
95% CI, 0.68-0.86
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study
